^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Melanoma
    Drug:Loqtorzi (toripalimab-tpzi) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

    Excerpt:
    ...Investigate potential biomarkers including the expression level of AdenoSig in tumor tissues`Investigate potential biomarkers including the TMB in tumor tissues`Investigate potential biomarkers including the MSI status in relationship to efficacy outcomes`Investigate potential biomarkers including the expression level of PD-L1 in tumor tissues`Investigate potential biomarkers including the expression level of CD68 in tumor tissues`Investigate potential biomarkers including the expression level of A2aR in tumor tissues`Investigate potential biomarkers including the expression level of CD8 in tumor tissues...
    Trial ID:
    NCT05955105
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    Four-year survival follow-up of toripalimab (JS001) as salvage therapy in Chinese melanoma patients

    Published date:
    05/19/2021
    Excerpt:
    The median OS of PD-L1+ (n = 26) and PD-L1- (n = 84) patients were 46.1 and 14.4 mo (P = 0.026, HR = 0.45, 95%CI 0.26-0.76)….Salvage treatment with toripalimab leads to long-term survival benefit in advanced melanoma patients, especially for those with non-acral cutaneous and unknown primary subtypes, CR/PR/SD as best response or PD-L1+.
    DOI:
    10.1200/JCO.2021.39.15_suppl.e21522
    Trial ID:
    NCT03013101
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial

    Published date:
    07/21/2020
    Excerpt:
    Patients with positive PD-L1 staining in tumor biopsies had significant better ORR (38.5% vs. 11.9%, P = 0.0065), PFS (7.7 months vs. 2.7 months, P = 0.013), and OS (not reached vs. 14.4 months, P = 0.0005) than PD-L1–negative patients….Toripalimab demonstrated a manageable safety profile and durable clinical response in Chinese patients with metastatic melanoma refractory to standard therapy.
    DOI:
    10.1158/1078-0432.CCR-19-3922